Pharmacokinetics and pharmacodynamics of nitric oxide mimetic agents

Palmer, 1987, Nitric oxide release accounts for the biological activity of endothelium-derived relaxing factor, Nature, 327, 524, 10.1038/327524a0 Fukuto, 2005, The physiological chemistry and biological activity of nitroxyl (HNO):  the neglected, misunderstood, and enigmatic nitrogen oxide, Chem. Res. Toxicol., 18, 790, 10.1021/tx0496800 Thomas, 2008, The chemical biology of nitric oxide: implications in cellular signaling, Free Radic. Biol. Med., 45, 18, 10.1016/j.freeradbiomed.2008.03.020 Lipton, 1993, A redox-based mechanism for the neuroprotective and neurodestructive effects of nitric oxide and related nitroso-compounds, Nature, 364, 626, 10.1038/364626a0 Arancio, 1996, Nitric oxide acts directly in the presynaptic neuron to produce long-term potentiation in cultured hippocampal neurons, Cell, 87, 1025, 10.1016/S0092-8674(00)81797-3 Hawkins, 1994, Nitric oxide and carbon monoxide as possible retrograde messengers in hippocampal long-term potentiation, J. Neurobiol., 25, 652, 10.1002/neu.480250607 Son, 1998, The specific role of cGMP in hippocampal LTP, Learn. Mem., 5, 231, 10.1101/lm.5.3.231 Ignarro, 1999, Nitric oxide: a unique endogenous signaling molecule in vascular biology, Biosci. Rep., 19, 51, 10.1023/A:1020150124721 Heinrich, 2013, Biological nitric oxide signalling: chemistry and terminology, Br. J. Pharmacol., 169, 1417, 10.1111/bph.12217 Lundberg, 2008, The nitrate-nitrite-nitric oxide pathway in physiology and therapeutics, Nat. Rev. Drug Discov., 7, 156, 10.1038/nrd2466 Amir, 2015, Furoxan derivatives as nitric oxide donors and their therapeutic potential, Int. Res. J. Pharm., 6, 585, 10.7897/2230-8407.069115 Huang, 2017, Nitric oxide donor-based cancer therapy: advances and prospects, J. Med. Chem., 60, 7617, 10.1021/acs.jmedchem.6b01672 Thatcher, 2005, An introduction to NO-related therapeutic agents, Curr. Top. Med. Chem., 5, 597, 10.2174/1568026054679281 Thatcher, 2006, NO chimeras as therapeutic agents in Alzheimer's disease, Curr. Alzheimer Res., 3, 237, 10.2174/156720506777632925 Wang, 2002, Nitric oxide donors: chemical activities and biological applications, Chem. Rev., 102, 1091, 10.1021/cr000040l Serafim, 2012, Nitric oxide: state of the art in drug design, Curr. Med. Chem., 19, 386, 10.2174/092986712803414321 Brunton, 1867, On the use of nitrite of amyl in angina pectoris, Lancet, 97, 10.1016/S0140-6736(02)51392-1 Murrell, 1879, Nitro-glycerine as a remedy for angina pectoris, Lancet, 80, 10.1016/S0140-6736(02)46032-1 Gorren, 2005, Effects of nitroglycerin/L-cysteine on soluble guanylate cyclase: evidence for an activation/inactivation equilibrium controlled by nitric oxide binding and haem oxidation, Biochem. J., 390, 625, 10.1042/BJ20050565 Beretta, 2008, Bioactivation of nitroglycerin by purified mitochondrial and cytosolic aldehyde dehydrogenases, J. Biol. Chem., 283, 17873, 10.1074/jbc.M801182200 Morris, 2003, Carrageenan-induced paw edema in the rat and mouse, Methods Mol. Biol., 225, 115 L'Episcopo, 2010, Combining nitric oxide release with anti-inflammatory activity preserves nigrostriatal dopaminergic innervation and prevents motor impairment in a 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model of Parkinson's disease, J. Neuroinflammation, 7, 10.1186/1742-2094-7-83 Weggen, 2001, A subset of NSAIDs lower amyloidogenic Abeta42 independently of cyclooxygenase activity, Nature, 414, 212, 10.1038/35102591 Czirr, 2006, Gamma-secretase modulation with Abeta42-lowering nonsteroidal anti-inflammatory drugs and derived compounds, Neurodegener. Dis., 3, 298, 10.1159/000095270 Kukar, 2007, Chronic administration of R-flurbiprofen attenuates learning impairments in transgenic amyloid precursor protein mice, BMC Neurosci., 8, 10.1186/1471-2202-8-54 Imbimbo, 2007, In vitro and in vivo profiling of CHF5022 and CHF5074: two β-amyloid1–42 lowering agents, Pharmacol. Res., 55, 318, 10.1016/j.phrs.2006.12.010 Abdul-Hay, 2009, NO-flurbiprofen reduces amyloid-beta, is neuroprotective in cell culture, and enhances cognition in response to cholinergic blockade, J. Neurochem., 111, 766, 10.1111/j.1471-4159.2009.06353.x Govoni, 2006, In vitro metabolism of (nitrooxy)butyl ester nitric oxide-releasing compounds: comparison with glyceryl trinitrate, J. Pharmacol. Exp. Therapeut., 317, 752, 10.1124/jpet.105.097469 Prosperi, 2004, Comparison between flurbiprofen and its nitric oxide-releasing derivatives HCT-1026 and NCX-2216 on Abeta(1-42)-induced brain inflammation and neuronal damage in the rat, Int. J. Immunopathol. Pharmacol., 17, 317, 10.1177/039463200401700312 Prosperi, 2001, NO-flurbiprofen attenuates excitotoxin-induced brain inflammation, and releases nitric oxide in the brain, Jpn. J. Pharmacol., 86, 230, 10.1254/jjp.86.230 Di, 2013, Demystifying brain penetration in central nervous system drug discovery. Miniperspective, Journal of medicinal chemistry, 56, 2, 10.1021/jm301297f Wallace, 2004, Gastric tolerability and prolonged prostaglandin inhibition in the brain with a nitric oxide-releasing flurbiprofen derivative, NCX-2216 [3-[4-(2-fluoro-alpha-methyl-[1,1'-biphenyl]-4-acetyloxy)-3-methoxyphenyl]-2-prop enoic acid 4-nitrooxy butyl ester], J. Pharmacol. Exp. Therapeut., 309, 626, 10.1124/jpet.103.063453 Idris, 2009, The nitrosylated flurbiprofen derivative HCT1026 inhibits cytokine-induced signalling through a novel mechanism of action, Eur. J. Pharmacol., 602, 215, 10.1016/j.ejphar.2008.11.023 Luo, 2016, A multifunctional therapeutic approach to disease modification in multiple familial mouse models and a novel sporadic model of Alzheimer's disease, Mol. Neurodegener., 11, 35, 10.1186/s13024-016-0103-6 Bennett, 2007, Cognitive deficits in rats after forebrain cholinergic depletion are reversed by a novel NO mimetic nitrate ester, Neuropsychopharmacology, 32, 505, 10.1038/sj.npp.1301054 van der Staay, 2008, The novel selective PDE9 inhibitor BAY 73-6691 improves learning and memory in rodents, Neuropharmacology, 55, 908, 10.1016/j.neuropharm.2008.07.005 Abdul-Hay, 2011, NO-SSRIs: nitric oxide chimera drugs incorporating a selective serotonin reuptake inhibitor, ACS Med. Chem. Lett., 2, 656, 10.1021/ml2000033 Horton, 2018, Furoxans (oxadiazole-4N-oxides) with attenuated reactivity are neuroprotective, cross the blood brain barrier, and improve passive avoidance memory, J. Med. Chem., 61, 4593, 10.1021/acs.jmedchem.8b00389 Ota, 2008, The NO-cGMP-PKG signaling pathway regulates synaptic plasticity and fear memory consolidation in the lateral amygdala via activation of ERK/MAP kinase, Learn. Mem., 15, 792, 10.1101/lm.1114808 Puzzo, 2009, Phosphodiesterase 5 inhibition improves synaptic function, memory, and amyloid-β load in an alzheimer's disease mouse model, J. Neurosci., 29, 8075, 10.1523/JNEUROSCI.0864-09.2009 Zhang, 2013, Phosphodiesterase-5 inhibitor sildenafil prevents neuroinflammation, lowers beta-amyloid levels and improves cognitive performance in APP/PS1 transgenic mice, Behav. Brain Res., 250, 230, 10.1016/j.bbr.2013.05.017 Vanmierlo, 2016, The PDE4 inhibitor roflumilast improves memory in rodents at non-emetic doses, Behav. Brain Res., 303, 26, 10.1016/j.bbr.2016.01.031 Brilli, 1985, Intratracheal instillation of a novel NO/nucleophile adduct selectively reduces pulmonary hypertension, Journal of applied physiology (Bethesda, Md, 83, 1968, 10.1152/jappl.1997.83.6.1968 Chattopadhyay, 2010, Comparison between 3-Nitrooxyphenyl acetylsalicylate (NO-ASA) and O2-(acetylsalicyloxymethyl)-1-(pyrrolidin-1-yl)diazen-1-ium-1,2-diolate (NONO-ASA) as safe anti-inflammatory, analgesic, antipyretic, antioxidant prodrugs, J. Pharmacol. Exp. Therapeut., 335, 443, 10.1124/jpet.110.171017 Velazquez, 2005, Novel nonsteroidal antiinflammatory drugs possessing a nitric oxide donor diazen-1-ium-1,2-diolate moiety: design, synthesis, biological evaluation, and nitric oxide release studies, J. Med. Chem., 48, 4061, 10.1021/jm050211k Lam, 2004, The selective pulmonary vasodilatory effect of inhaled DETA/NO, a novel nitric oxide donor, in ARDS-a pilot human trial, J. Crit. Care, 19, 48, 10.1016/j.jcrc.2004.02.009 Lam, 2002, The effects of inhalation of a novel nitric oxide donor, DETA/NO, in a patient with severe hypoxaemia due to acute respiratory distress syndrome, Anaesth. Intensive Care, 30, 472, 10.1177/0310057X0203000413 Feelisch, 1989, On the mechanism of NO release from sydnonimines, J. Cardiovasc. Pharmacol., 14, S13, 10.1097/00005344-198914110-00004 Schrammel, 1998, Activation of soluble guanylyl cyclase by the nitrovasodilator 3-morpholinosydnonimine involves formation of S-nitrosoglutathione, Mol. Pharmacol., 54, 207, 10.1124/mol.54.1.207 Rudolph, 1991, Clinical comparison of nitrates and sydnonimines, Eur. Heart J., 12, 33, 10.1093/eurheartj/12.suppl_E.33 Kelly, 1996, Nitric oxide and nitrovasodilators: similarities, differences, and interactions, Am. J. Cardiol., 77, 2c, 10.1016/S0002-9149(96)00182-8 Meinertz, 1985, Relationship between pharmacokinetics and pharmacodynamics of molsidomine and its metabolites in humans, Am. Heart J., 109, 644, 10.1016/0002-8703(85)90671-4 Chugunova, 2017, Novel structural hybrids on the base of benzofuroxans and furoxans. Mini-review, Curr. Top. Med. Chem., 17, 986, 10.2174/1568026616666160927145822 Martens-Lobenhoffer, 2010, Improved method for the determination of cyclic guanosine monophosphate (cGMP) in human plasma by LC–MS/MS, J. Chromatogr. B, 878, 487, 10.1016/j.jchromb.2009.12.009 Horton, 2018, Furoxans (Oxadiazole-4N-oxides) with attenuated reactivity are neuroprotective, cross the blood brain barrier, and improve passive avoidance memory, J. Med. Chem., 61, 4593, 10.1021/acs.jmedchem.8b00389 Liu, 1997, Nitric oxide donors: effects of S-nitrosoglutathione and 4-phenyl-3-furoxancarbonitrile on ocular blood flow and retinal function recovery, J. Ocul. Pharmacol. Therapeut, 13, 105, 10.1089/jop.1997.13.105 Li, 2015, High-throughput screening against thioredoxin glutathione reductase identifies novel inhibitors with potential therapeutic value for schistosomiasis, Infectious diseases of poverty, 4, 10.1186/s40249-015-0071-z Medana, 1994, Furoxans as nitric oxide donors. 4-Phenyl-3-furoxancarbonitrile: thiol-mediated nitric oxide release and biological evaluation, J. Med. Chem., 37, 4412, 10.1021/jm00051a020 Buckley, 2008, Keap1 modification and nuclear accumulation in response to S-nitrosocysteine, Free Radic. Biol. Med., 44, 692, 10.1016/j.freeradbiomed.2007.10.055 Um, 2011, Nitric oxide activates Nrf2 through S-nitrosylation of Keap1 in PC12 cells, Nitric Oxide : biology and chemistry, 25, 161, 10.1016/j.niox.2011.06.001 Cabrera, 2016, In vivo phase II-enzymes inducers, as potential chemopreventive agents, based on the chalcone and furoxan skeletons, Bioorg. Med. Chem., 24, 1665, 10.1016/j.bmc.2016.02.041 Singh, 1996, Mechanism of nitric oxide release from S-nitrosothiols, J. Biol. Chem., 271, 18596, 10.1074/jbc.271.31.18596 Cena, 2003, Antiinflammatory, gastrosparing, and antiplatelet properties of new NO-donor esters of aspirin, J. Med. Chem., 46, 747, 10.1021/jm020969t Lazzarato, 2011, Searching for new NO-donor aspirin-like molecules: furoxanylacyl derivatives of salicylic acid and related furazans, Bioorg. Med. Chem., 19, 5852, 10.1016/j.bmc.2011.08.018 Balbo, 2008, Studies of the potential genotoxic effects of furoxans: the case of CAS 1609 and of the water-soluble analogue of CHF 2363, Toxicol. Lett., 178, 44, 10.1016/j.toxlet.2008.02.001 Bohn, 1995, Cardiovascular actions of the furoxan CAS 1609, a novel nitric oxide donor, Br. J. Pharmacol., 114, 1605, 10.1111/j.1476-5381.1995.tb14946.x Sumimoto, 1993, Effects of glyceryl trinitrate on blood pressure and arterial compliance, Angiology, 44, 951, 10.1177/000331979304401205 Civelli, 1996, The involvement of the release of nitric oxide in the pharmacological activity of the new furoxan derivative CHF 2363, Br. J. Pharmacol., 118, 923, 10.1111/j.1476-5381.1996.tb15487.x Cabrera, 1977, Genetic toxicology and preliminary in vivo studies of nitric oxide donor tocopherol analogs as potential new class of antiatherogenic agents, Drug Chem. Toxicol., 34, 285, 10.3109/01480545.2010.536769 Balbo, 2008, Studies of the potential genotoxic effects of furoxans: the case of CAS 1609 and of the water-soluble analogue of CHF 2363, Toxicol. Lett., 178, 44, 10.1016/j.toxlet.2008.02.001 Boiani, 2004, Cytotoxicity of furoxans: quantitative structure-activity relationships study, Farmaco, 59, 405, 10.1016/j.farmac.2003.12.011 Huang, 2015, The furoxan nitric oxide donor, PRG150, evokes dose-dependent analgesia in a rat model of painful diabetic neuropathy (PDN), Clin. Exp. Pharmacol. Physiol., 42, 921, 10.1111/1440-1681.12442 Lotfipour, 2018, Morphine hyposensitivity in streptozotocin-diabetic rats: reversal by dietary L-arginine treatment, Clin. Exp. Pharmacol. Physiol., 45, 42, 10.1111/1440-1681.12855 Pippin, 2016, In vitro metabolic stability and in vivo biodistribution of 3-Methyl-4-furoxancarbaldehyde using PET imaging in rats, ACS Med. Chem. Lett., 7, 563, 10.1021/acsmedchemlett.5b00410 Schiefer, 2012, Furoxans (1,2,5-oxadiazole-N-oxides) as novel NO mimetic neuroprotective and procognitive agents, J. Med. Chem., 55, 3076, 10.1021/jm201504s Haley, 1992, The role of nitric oxide in hippocampal long-term potentiation, Neuron, 8, 211, 10.1016/0896-6273(92)90288-O Zhuo, 1994, Role of guanylyl cyclase and cGMP-dependent protein kinase in long-term potentiation, Nature, 368, 635, 10.1038/368635a0 Lu, 1999, Nitric oxide signaling contributes to late-phase LTP and CREB phosphorylation in the hippocampus, J. Neurosci., 19, 10250, 10.1523/JNEUROSCI.19-23-10250.1999 Bon, 2003, On the role of nitric oxide in hippocampal long-term potentiation, J. Neurosci., 23, 1941, 10.1523/JNEUROSCI.23-05-01941.2003 Puzzo, 2005, Amyloid-beta peptide inhibits activation of the nitric oxide/cGMP/cAMP-responsive element-binding protein pathway during hippocampal synaptic plasticity, J. Neurosci., 25, 6887, 10.1523/JNEUROSCI.5291-04.2005 Paul, 2010, cGMP-dependent protein kinase type I promotes CREB/CRE-mediated gene expression in neurons of the lateral amygdala, Neurosci. Lett., 473, 82, 10.1016/j.neulet.2010.02.020 Tao, 1998, Ca2+ influx regulates BDNF transcription by a CREB family transcription factor-dependent mechanism, Neuron, 20, 709, 10.1016/S0896-6273(00)81010-7 Hu, 1999, Regulation of CBP-mediated transcription by neuronal calcium signaling, Neuron, 22, 799, 10.1016/S0896-6273(00)80738-2 Mayr, 2001, Transcriptional regulation by the phosphorylation-dependent factor CREB, Nat. Rev. Mol. Cell Biol., 2, 599, 10.1038/35085068 Caccamo, 2010, CBP gene transfer increases BDNF levels and ameliorates learning and memory deficits in a mouse model of Alzheimer's disease, Proc. Natl. Acad. Sci. U. S. A., 107, 22687, 10.1073/pnas.1012851108 Conti, 2002, cAMP response element-binding protein is essential for the upregulation of brain-derived neurotrophic factor transcription, but not the behavioral or endocrine responses to antidepressant drugs, J. Neurosci., 22, 3262, 10.1523/JNEUROSCI.22-08-03262.2002 Ying, 2002, Brain-derived neurotrophic factor induces long-term potentiation in intact adult hippocampus: requirement for ERK activation coupled to CREB and upregulation of Arc synthesis, J. Neurosci., 22, 1532, 10.1523/JNEUROSCI.22-05-01532.2002 Zha, 2001, BDNF synthesis in spiral ganglion neurons is constitutive and CREB-dependent, Hear. Res., 156, 53, 10.1016/S0378-5955(01)00267-2 Shieh, 1999, Molecular mechanisms underlying activity-dependent regulation of BDNF expression, J. Neurobiol., 41, 127, 10.1002/(SICI)1097-4695(199910)41:1<127::AID-NEU16>3.0.CO;2-J Miller, 2010, Amyloid-beta inhibits No-cGMP signaling in a CD36- and CD47-dependent manner, PLoS One, 5, 10.1371/journal.pone.0015686 Baltrons, 2002, Beta-amyloid peptides decrease soluble guanylyl cyclase expression in astroglial cells, Neurobiol. Dis., 10, 139, 10.1006/nbdi.2002.0492 Lu, 1999, Nitric oxide signaling contributes to late-phase LTP and CREB phosphorylation in the hippocampus, J. Neurosci., 19 Ciani, 2002, Nitric oxide regulates cGMP-dependent cAMP-responsive element binding protein phosphorylation and Bcl-2 expression in cerebellar neurons: implication for a survival role of nitric oxide, J. Neurochem., 82, 1282, 10.1046/j.1471-4159.2002.01080.x Luo, 2014 Abdul-Hay, S.; Sutherland, R. J.; Reynolds, J. N.; Bennett, B. M.; Thatcher, G. R. J., GT 1061, A novel nitrate ester in clinical trials for Alzheimer's disease, enhances cognitive performance in rats with forebrain cholinergic depletion. Abstracts, 37th Great Lakes Regional Meeting of the American Chemical Society, Milwaukee, WI, United States, May 31-June 2 2006, GLRM-152. Gong, 2004, Persistent improvement in synaptic and cognitive functions in an Alzheimer mouse model after rolipram treatment, J. Clin. Invest., 114, 1624, 10.1172/JCI22831 Vitolo, 2002, Amyloid beta -peptide inhibition of the PKA/CREB pathway and long-term potentiation: reversibility by drugs that enhance cAMP signaling, Proc. Natl. Acad. Sci. U. S. A., 99, 13217, 10.1073/pnas.172504199 Davis, 2005, Rolipram attenuates MK-801-induced deficits in latent inhibition, Behav. Neurosci., 119, 595, 10.1037/0735-7044.119.2.595 Nakagawa, 2002, Regulation of neurogenesis in adult mouse hippocampus by cAMP and the cAMP response element-binding protein, J. Neurosci., 22, 3673, 10.1523/JNEUROSCI.22-09-03673.2002 Puzzo, 2009, Phosphodiesterase 5 inhibition improves synaptic function, memory, and amyloid-beta load in an Alzheimer's disease mouse model, J. Neurosci., 29, 8075, 10.1523/JNEUROSCI.0864-09.2009 Tagliaro, 1996, Pharmacokinetics of a new nitroderivative of acetylsalicylic acid after a single dose in rats, Life Sci., 60, 101, 10.1016/S0024-3205(96)00599-1 Cuzzolin, 1996, Effect of single and repeated doses of a new nitroderivative of acetylsalicylic acid on platelet TXA2 production in rats, Life Sci., 58, PL207, 10.1016/0024-3205(96)00038-0 Wallace, 1995, Nitric oxide-releasing NSAIDs: a novel class of GI-sparing anti-inflammatory drugs, Agents Actions Suppl., 46, 121 Armour, 2001, vol. 44, 2185 Idris, 2009, The nitrosylated flurbiprofen derivative HCT1026 inhibits cytokine-induced signalling through a novel mechanism of action, Eur. J. Pharmacol., 602, 215, 10.1016/j.ejphar.2008.11.023 Schiefer, 2011, Inhibition of amyloidogenesis by nonsteroidal anti-inflammatory drugs and their hybrid nitrates, J. Med. Chem., 54, 2293, 10.1021/jm101450p Bennett, 2007, Cognitive deficits in rats after forebrain cholinergic depletion are reversed by a novel NO mimetic nitrate ester, Neuropsychopharmacology, 32, 505, 10.1038/sj.npp.1301054 Qin, 2012, Design and synthesis of neuroprotective methylthiazoles and modification as NO-chimeras for neurodegenerative therapy, J. Med. Chem., 55, 6784, 10.1021/jm300353r Bohn, 1995, Cardiovascular actions of the furoxan CAS 1609, a novel nitric oxide donor, Br. J. Pharmacol., 114, 1605, 10.1111/j.1476-5381.1995.tb14946.x Civelli, 1996, The involvement of the release of nitric oxide in the pharmacological activity of the new furoxan derivative CHF 2363, Br. J. Pharmacol., 118, 923, 10.1111/j.1476-5381.1996.tb15487.x Huang, 2015, The furoxan nitric oxide donor, PRG150, evokes dose-dependent analgesia in a rat model of painful diabetic neuropathy, Clin. Exp. Pharmacol. Physiol., 42, 921, 10.1111/1440-1681.12442 Pippin, 2016, In vitro metabolic stability and in vivo biodistribution of 3-Methyl-4-furoxancarbaldehyde using PET imaging in rats, ACS Med. Chem. Lett., 7, 563, 10.1021/acsmedchemlett.5b00410